HK1026138A1 - Aqueous suspension for nasal administration of loteprednol - Google Patents

Aqueous suspension for nasal administration of loteprednol

Info

Publication number
HK1026138A1
HK1026138A1 HK00104645A HK00104645A HK1026138A1 HK 1026138 A1 HK1026138 A1 HK 1026138A1 HK 00104645 A HK00104645 A HK 00104645A HK 00104645 A HK00104645 A HK 00104645A HK 1026138 A1 HK1026138 A1 HK 1026138A1
Authority
HK
Hong Kong
Prior art keywords
loteprednol
aqueous suspension
nasal administration
nasal
administration
Prior art date
Application number
HK00104645A
Other languages
English (en)
Inventor
Koji Doi
Original Assignee
Nicholas Bodor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Bodor filed Critical Nicholas Bodor
Publication of HK1026138A1 publication Critical patent/HK1026138A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HK00104645A 1997-01-16 2000-07-26 Aqueous suspension for nasal administration of loteprednol HK1026138A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1966497 1997-01-16
PCT/JP1998/000108 WO1998031343A2 (en) 1997-01-16 1998-01-14 Aqueous suspension for nasal administration of loteprednol

Publications (1)

Publication Number Publication Date
HK1026138A1 true HK1026138A1 (en) 2000-12-08

Family

ID=12005518

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00104645A HK1026138A1 (en) 1997-01-16 2000-07-26 Aqueous suspension for nasal administration of loteprednol

Country Status (33)

Country Link
US (1) US6368616B1 (de)
EP (1) EP0973501B1 (de)
KR (1) KR100471708B1 (de)
CN (1) CN1126535C (de)
AR (1) AR011773A1 (de)
AT (1) ATE249205T1 (de)
AU (1) AU730953C (de)
BR (1) BR9806771A (de)
CA (1) CA2278025C (de)
CZ (1) CZ294919B6 (de)
DE (1) DE69818026T2 (de)
DK (1) DK0973501T3 (de)
EA (1) EA001775B1 (de)
ES (1) ES2206880T3 (de)
HK (1) HK1026138A1 (de)
HU (1) HU226613B1 (de)
ID (1) ID21892A (de)
IL (1) IL130979A0 (de)
LT (1) LT4677B (de)
LV (1) LV12449B (de)
MX (1) MXPA99006628A (de)
NO (1) NO324619B1 (de)
NZ (2) NZ509908A (de)
PL (1) PL190753B1 (de)
PT (1) PT973501E (de)
RS (1) RS49701B (de)
SI (1) SI20057A (de)
SK (1) SK283164B6 (de)
TR (1) TR199901663T2 (de)
TW (1) TW503113B (de)
UA (1) UA52722C2 (de)
WO (1) WO1998031343A2 (de)
ZA (1) ZA98303B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6428805B1 (en) * 1998-08-26 2002-08-06 Teijin Limited Powdery nasal compositions
DE19947235A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
ATE526973T1 (de) * 2001-06-18 2011-10-15 Noven Pharma Verbesserte arzneimittelabgabe in transdermalen systemen
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
EP1658083B1 (de) * 2003-06-19 2007-08-08 BODOR, Nicholas S. Verstärkung der aktivität und/oder wirkdauer von ausgewählten entzündungshemmenden steroiden
DE602004025002D1 (de) 2003-06-19 2010-02-25 Nicholas S Bodor Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti-entzündungswirkung für topische oder lokale verabreichung
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
CA2560824A1 (en) 2004-03-25 2005-10-13 Bausch & Lomb Incorporated Use of loteprednol etabonate for the treatment of dry eye
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US20070110812A1 (en) * 2005-11-14 2007-05-17 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
AU2012312816A1 (en) 2011-09-22 2014-04-24 Bausch & Lomb Incorporated Ophthalmic gel compositions
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
CN115135305A (zh) 2020-02-18 2022-09-30 诺和诺德股份有限公司 药物制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP0709099A3 (de) 1994-09-28 1996-07-24 Senju Pharma Co Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액

Also Published As

Publication number Publication date
ID21892A (id) 1999-08-05
KR20000070214A (ko) 2000-11-25
MXPA99006628A (es) 2005-01-10
EP0973501B1 (de) 2003-09-10
ZA98303B (en) 1998-07-20
HU226613B1 (en) 2009-04-28
NZ509908A (en) 2004-12-24
NZ336990A (en) 2001-03-30
LV12449A (lv) 2000-04-20
SI20057A (sl) 2000-04-30
CN1250370A (zh) 2000-04-12
TR199901663T2 (xx) 1999-09-21
DE69818026D1 (de) 2003-10-16
AU730953C (en) 2002-02-07
SK94899A3 (en) 2000-05-16
NO993453L (no) 1999-07-13
PT973501E (pt) 2004-02-27
ES2206880T3 (es) 2004-05-16
IL130979A0 (en) 2001-01-28
NO993453D0 (no) 1999-07-13
DK0973501T3 (da) 2004-01-19
CA2278025A1 (en) 1998-07-23
BR9806771A (pt) 2000-05-16
EP0973501A2 (de) 2000-01-26
RS49701B (sr) 2007-12-31
NO324619B1 (no) 2007-11-26
HUP0002473A2 (hu) 2000-12-28
PL190753B1 (pl) 2006-01-31
AR011773A1 (es) 2000-09-13
UA52722C2 (uk) 2003-01-15
KR100471708B1 (ko) 2005-03-07
EA199900659A1 (ru) 2000-02-28
CN1126535C (zh) 2003-11-05
CZ237499A3 (cs) 2000-01-12
LT4677B (lt) 2000-07-25
WO1998031343A2 (en) 1998-07-23
AU5495298A (en) 1998-08-07
CA2278025C (en) 2005-09-06
HUP0002473A3 (en) 2001-01-29
LV12449B (en) 2000-09-20
PL334614A1 (en) 2000-03-13
SK283164B6 (sk) 2003-03-04
AU730953B2 (en) 2001-03-22
CZ294919B6 (cs) 2005-04-13
YU36199A (sh) 2002-09-19
WO1998031343A3 (en) 1998-09-17
EA001775B1 (ru) 2001-08-27
ATE249205T1 (de) 2003-09-15
US6368616B1 (en) 2002-04-09
LT99100A (en) 2000-02-25
DE69818026T2 (de) 2004-07-08
TW503113B (en) 2002-09-21

Similar Documents

Publication Publication Date Title
HK1026138A1 (en) Aqueous suspension for nasal administration of loteprednol
GB2303064B (en) Medicament for nasal administration
GB9726916D0 (en) Nasal formulation
PL318132A1 (en) Aqueous preparations of risperidone
EP0747078A3 (de) Nasenmaske
HRP960300B1 (en) Inhaler for administration of blister-packed medicaments
AU730196C (en) Aqueous suspension of loteprednol etabonate
ZA964188B (en) Nasal applicator
AU1403199A (en) Local delivery of therapeutic agents
AU144048S (en) Nasal mask
HUP9903541A3 (en) Nasal administration of desmopressin
PL342345A1 (en) Active substance suspension for oral administration
AU3290595A (en) An aqueous nasal suspension
GB9414966D0 (en) Pharmaceutical compositions for the nasal administration of antiviral agents
AU144044S (en) Nasal mask
AU7449698A (en) Therapeutic agents for respiratory diseases
PL335675A1 (en) Anticonvulsive derivatives of isoquinolinbenzamide
GB9721597D0 (en) (Nasal) breathing aid
CA79927S (en) Nasal mask
AU128435S (en) Nasal inhaler
GB2332626B (en) Medicaments for treatment of disorders of the middle ear
PL57880Y1 (en) Folded model of geometrical body of revolution-sphere
ZA977042B (en) Nasal administration of agents for treatment of delayed onset emesis.
GB9727275D0 (en) Medicaments for treatment of disorders of the middle ear

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100114